Log on / register
Feedback | Support | My details
Open AccessResearch article

An extensive phenotypic characterization of the hTNFα transgenic mice

Michael D Hayward* email, Beverly K Jones* email, Arman Saparov email, Heather S Hain email, Anne-Cecile Trillat email, Michelle M Bunzel email, Aaron Corona email, Bifang Li-Wang email, Bryan Strenkowski email, Caroline Giordano email, Hai Shen email, Emily Arcamone email, Jeffrey Weidlick email, Maria Vilensky email, Marina Tugusheva email, Roland H Felkner email, William Campbell email, Yu Rao email, David S Grass email and Olesia Buiakova email

Caliper Discovery Alliances & Services (Xenogen Biosciences), 5 Cedar Brook Drive, Cranbury, NJ 08512, USA

author email corresponding author email* Contributed equally

BMC Physiology 2007, 7:13doi:10.1186/1472-6793-7-13

Published: 10 December 2007

Abstract

Background

Tumor necrosis factor alpha (TNFα) is implicated in a wide variety of pathological and physiological processes, including chronic inflammatory conditions, coronary artery disease, diabetes, obesity, and cachexia. Transgenic mice expressing human TNFα (hTNFα) have previously been described as a model for progressive rheumatoid arthritis. In this report, we describe extensive characterization of an hTNFα transgenic mouse line.

Results

In addition to arthritis, these hTNFα transgenic mice demonstrated major alterations in body composition, metabolic rate, leptin levels, response to a high-fat diet, bone mineral density and content, impaired fertility and male sexual function. Many phenotypes displayed an earlier onset and a higher degree of severity in males, pointing towards a significant degree of sexual dimorphism in response to deregulated expression of TNFα.

Conclusion

These results highlight the potential usefulness of this transgenic model as a resource for studying the progressive effects of constitutively expressed low levels of circulating TNFα, a condition mimicking that observed in a number of human pathological conditions.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.